Preferred Pharmaceuticals — Class II drug recall D-0797-2020
Terminated recall by Preferred Pharmaceuticals, Inc, reported 2020-01-29, distributed in AL, AZ, CA, FL, GA, IN, SC. CGMP Deviations: Presence of NDMA impurity detected in product.
| Recall number | D-0797-2020 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Preferred Pharmaceuticals, Inc, Anaheim, CA, United States |
| Recall initiated | 2020-01-07 |
| Classified | 2020-01-20 |
| Reported by FDA | 2020-01-29 |
| Terminated | 2023-12-14 |
| Distributed | AL, AZ, CA, FL, GA, IN, SC |
| Quantity | 39,172 tablets |
| Reason classes | chemical contamination, cgmp, specification failure |
| NDC | 68788-6382-00, 68788-6382-01, 68788-6382-03, 68788-6382-09 |
Product
Preferred Pharmaceuticals, Inc, Ranitidine Tablets, 300 mg, Rx Only, a) 14 count bottles (NDC: 68788-6382-1), b) 30 count bottles (NDC: 68788-6382-3), c) 90 count bottles (NDC: 68788-6382-9), d) 100 count bottles (NDC: 68788-6382-0)
Reason for recall
CGMP Deviations: Presence of NDMA impurity detected in product.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0797-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.